Peptide Sciences Shut Down: A Timeline of What Happened

On March 6, 2026, visitors to peptidesciences.com found a short statement in place of the storefront: the company had decided to 'voluntarily shut down operations and discontinue the sale of our research products.' No detail was given on outstanding orders or refunds. For a vendor widely considered the largest US research-peptide supplier by revenue — an estimated $7.4 million in online sales in December 2025 alone, per Grips Intelligence — the closure landed as the most consequential single event in the category's recent history.

The 18 months before the closure

Peptide Sciences didn't close in a vacuum. Its shutdown followed roughly a year and a half of escalating federal enforcement across the research-peptide industry as a whole.

• A June 2025 FDA warehouse raid on a competing vendor marked a shift from administrative warning letters to physical enforcement action.
• By September 2025, the FDA had issued more than 50 warning letters industry-wide.
• The proposed SAFE Drugs Act specifically targeted research-chemical analogs of FDA-approved drugs.
• HHS announced moving roughly 14 of 19 restricted peptides back to Category 1 status — prescription-only, dispensed through compounding pharmacies rather than sold as research chemicals.

What the closure signals about the market

Peptide Sciences had operated for over a decade as something close to a default recommendation across the research-peptide community, which is precisely why its exit matters more as a signal than as an isolated business failure. A vendor with that much revenue, tenure, and brand recognition chose to close rather than continue operating under the current regulatory trajectory. That decision is consistent with the broader pattern we've documented across the category: within roughly nine months, at least eight major vendors — including Science.bio, Amino Asylum, Paradigm Peptides, and others — either closed voluntarily or were shut down by federal action.

Any website currently using the Peptide Sciences name or branding is confirmed fraudulent. The company stated plainly that no relaunch or successor exists.

Where researchers have migrated

In the wake of the closure, community discussion and third-party review coverage have pointed toward a mix of longer-tenured vendors and newer, documentation-focused storefronts as replacements. None of them inherit Peptide Sciences' track record — that history closed with the company. What buyers can do instead is evaluate each alternative on its own current documentation and reputation rather than assuming brand recognition alone is a substitute for verification.

A few vendors we've reviewed independently and that show up repeatedly in post-closure discussion:

• SwissChems — one of the more frequently cited legacy alternatives after the shutdown, though our own review flags an unresolved December 2024 FDA warning letter and mixed 2026 reports on order fulfillment, which is why we rate it 'caution' rather than a straightforward recommendation.
• Pure Rawz — a long-running vendor (since 2018) with a named third-party lab (MZ Biolabs) and per-batch COAs published on product pages before checkout.
• Protide Health — a newer entrant with a verifiable lab relationship (Freedom Diagnostics) that publishes searchable accession codes per COA, alongside fast, clearly documented US shipping.

The pattern across this closure wave is consistent: tenure alone no longer predicts continuity, and documentation that can be independently verified matters more now than it did when Peptide Sciences was the default choice. See our broader look at the 2025-2026 closure wave for the full pattern across vendors.